What is the history of BPES - Blepharophimosis Ptosis Epicanthus Inversus Syndrome?

Blepharophimosis Ptosis Epicanthus Inversus Syndrome (BPES) was first formally characterized in the early 20th century as a distinct clinical entity involving specific eyelid malformations. Today, we understand BPES as a genetic condition primarily caused by mutations in the FOXL2 gene, allowing for precise molecular diagnosis and improved surgical management.

When was BPES first identified in medical literature?

While the physical features of Blepharophimosis Ptosis Epicanthus Inversus Syndrome were observed by various ophthalmologists in the 19th century, it was the French ophthalmologist Alexandre-Pierre-Auguste von Ammon who first described the condition in 1841. However, the syndrome was formally established as a specific clinical entity in 1921 by the physician Vignes, who recognized the consistent combination of its four cardinal features: blepharophimosis (narrowing of the eye opening), ptosis (drooping eyelids), epicanthus inversus (skin folds), and telecanthus (increased distance between the inner corners of the eyes).

How has our understanding of BPES evolved?

For decades, BPES was categorized solely by its physical presentation. A major milestone occurred in 1983 when the condition was linked to chromosome 3q. The most significant leap forward occurred in 2001, when researchers identified the FOXL2 gene as the causative factor. This discovery allowed clinicians to distinguish between two types of Blepharophimosis Ptosis Epicanthus Inversus Syndrome:

• Type I: Includes the characteristic eyelid features plus premature ovarian insufficiency (POI) in females.


• Type II: Includes only the eyelid features without associated ovarian dysfunction.

How have treatment and advocacy changed?

Historically, surgical correction for BPES was often attempted in a single stage, which frequently led to poor functional outcomes. Modern surgical techniques now emphasize a multi-stage approach—first correcting the telecanthus and epicanthal folds, followed by ptosis repair. Patient advocacy has also transformed the landscape; at DiseaseMaps.org, 70 members have united to share experiences, moving the focus from purely aesthetic concerns to the long-term management of ovarian health and psychological well-being.

Next steps

• Consult a clinical geneticist to discuss FOXL2 testing and family planning.


• Schedule regular consultations with an oculoplastic surgeon specializing in congenital ptosis.


• Connect with the community at DiseaseMaps.org to share experiences with others living with Blepharophimosis Ptosis Epicanthus Inversus Syndrome.

Medical disclaimer: This content is for informational purposes only and does not constitute professional medical advice, diagnosis, or treatment.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Blepharophimosis, ptosis, and epicanthus inversus syndrome.


• OMIM (Online Mendelian Inheritance in Man): #110100 BLEPHAROPHIMOSIS, PTOSIS, AND EPICANTHUS INVERSUS SYNDROME; BPES.


• Orphanet: Blepharophimosis-ptosis-epicanthus inversus syndrome.


• Crisponi, L., et al. (2001). "The FOXL2 gene is mutated in blepharophimosis/ptosis/epicanthus inversus syndrome (BPES)." Nature Genetics.